(Sharecast News) - Drugmaker Astrazeneca received a double boost on Monday as European regulators issued positive opinions for two of its medicines - Klygefa for generalised myasthenia gravis and Enhertu for early‑stage HER2‑positive breast cancer.
Astrazeneca said the EU's Committee for Medicinal Products for Human Use had backed Klygefa (gefurulimab) for...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE